Why Amgen Paid 14x Forward Revenue for Horizon
When Amgen moved to acquire Horizon Therapeutics for $27.8 billion, the headline price immediately grabbed attention, but the real focus for investors was on the multiples. At roughly 14 times projected 2023 revenue and nearly 40 times EBITDA, the deal hit heights not seen since the last boom in rare disease M&A. For context, AstraZeneca’s Alexion deal landed at 10x revenue back in 2021, and BioMarin, another rare disease player, still trades closer to the 7-9x range.
The contrast with Amgen’s own track record is even more pronounced. Just a few years back, Amgen took Otezla off Celgene’s hands at less than 8x sales. So what changed? In Horizon, Amgen is buying two rare disease engines that don’t just deliver growth, but also sport real insulation from generic erosion and PBM discounting: Tepezza (thyroid eye disease) and Uplizna (neuromyelitis optica spectrum disorder). Tepezza, for example, brought in $1.7 billion in 2022 despite a supply hiccup, and without it, growth would have run well into the double digits. Rare disease pipelines like this always carry a premium. Payers tolerate higher prices. Generic and biosimilar competition has a hard time getting a foothold. Amgen gets predictable cash.
Still, there’s a flip side. Horizon’s growth hangs precariously on just three products, over 80% of revenue centers on Tepezza, Uplizna, and Krystexxa (gout). One clinical setback, or a shift in payer stances, and the whole thesis wobbles. Amgen’s answer? Leverage its scale to bulk up these brands and unlock global opportunities Horizon never touched. A bet, plain and simple, that Tepezza can double its market if new indications pan out.
How Rare Disease Assets Buck Conventional Economics
During the deal roadshow, Amgen’s management hammered home the appeal of rare disease reimbursement. These therapies command sky-high list prices, Tepezza’s $300,000 per patient per year is just the most obvious example. For specialty pharmacies, that beats the constant churn of formulary management in broader categories. Pull the reimbursement data from RxInfo.ai and you’ll see what Amgen saw: rare disease drugs keep 70-80% of their sticker price, while primary care brands are lucky to net 30-40% after rebates and PBM shenanigans.
Gross margins? Often cresting 80%. That cash, more than the promise of a pipeline, is what underwrites the big multiples. And yes, Horizon’s early-stage pipeline does bring the possibility of follow-ons for Uplizna and some new programs in autoimmune disease. Amgen’s R&D capacity will likely speed things up. Still, there’s risk. Reimbursement could get tighter if PBMs, hunting for new savings, decide to go after rare disease drugs too. Until now, orphan therapies have sailed through, but nobody really knows how long that window stays open. Track those PBM moves on RxPBM.ai.
Global reach is the next lever. With a far larger international footprint, Amgen can launch Tepezza and Uplizna in Europe and other ex-US markets, potentially $500 million or more in additional sales, assuming pricing holds. That’s how AstraZeneca fueled Alexion’s next phase, and Amgen is poised to run that same playbook. Of course, easier said than done.
All-Cash Deals, Tightening Leverage, and the Cost of Optionality
Amgen’s approach to the $27.8B price tag? All cash, funded through a blend of new debt and cash reserves. Pro forma net leverage? Swelled to 4.5x EBITDA from less than half that. Not a number Amgen investors are used to seeing. Their IR team talked up plans to bring leverage below 3x in three years by blending Horizon’s cash flows with $500 million in projected annual cost synergies. Whether that happens on schedule is anyone’s guess.
Loading up the balance sheet has consequences. Amgen’s management says they’ll keep doing business development, but in practice, there’s little room left for substantial acquisitions until the debt load falls. Early-stage risk bets, expensive ones, at least, get crowded out by interest payments. Yet the thesis holds if Tepezza and Uplizna keep compounding at a double-digit clip. If growth stumbles? Amgen will face some hard choices: prioritize R&D, or lean into shareholder returns. Not both.
The usual “EPS accretion” headline feels almost beside the point. The real hurdle is integration. Horizon’s sales force is lean, and U.S.-centric. Amgen must avoid channel conflicts, keep the best people, and pull off global launches. Otherwise, that 14x revenue multiple could turn painful in a hurry.
On Pipeline, Payer Pressure, and What’s Really at Stake
Horizon’s pipeline looks modest on paper, programs for IgG4-related disease, myasthenia gravis, and some others. No instant blockbusters. Still, Amgen’s infrastructure can push these forward faster, using its clinical networks and global regulatory muscle. That’s one edge in a rare disease landscape where every patient counts, and pharma heavyweights jostle for even single-digit share gains. The operational efficiencies aren’t revolutionary, but they matter at this scale.
PBM scrutiny, meanwhile, is ratcheting up. In late 2023, several employer coalitions began to question the economics of therapies like Tepezza. Specialty pharmacies saw some rare disease margins squeezed as PBMs started trialing new restrictions, site-of-care edits, clinical step requirements. Today, Tepezza and Uplizna are largely protected. But if exclusion lists grow, Amgen’s topline could suffer a real dent. For a close-up on drug reimbursement shifts, RxBenefits.ai is the place to watch. Nobody’s immune forever.
Here’s the broader play: Amgen is leaning hard into rare diseases, a segment where big-cap biotech can still, frankly, find growth. It’s a high-stakes, high-concentration bet, driven by payer willingness, pipeline optionality, and global expansion. If Tepezza delivers and follow-ons mature, the price premium gets forgotten. If reimbursement cracks or growth slows, that 14x might look like the peak of a frothy market cycle. Personally, I’d say Amgen had little choice if it wanted to stay relevant in the next phase of biopharma, but they paid up.
So, rare disease economics still rule. For now. The next few years will show which side of rare Amgen actually bought.
